Nexalin Technology's Chief Medical Officer Invests $7,700 in Company Stock Amidst Market Volatility
In a notable move, the Chief Medical Officer of Nexalin Technology, Inc. (NASDAQ:NXL) has purchased $7,700 worth of common stock. This investment comes at a time when the stock has experienced significant fluctuations, with a 18% drop in the past week, despite achieving an impressive 607% gain over the last year. The company's stock performance has been closely watched by investors, with many tracking its progress in the medical technology sector. With this investment, the Chief Medical Officer is demonstrating confidence in the company's future prospects. Nexalin Technology's innovative solutions and strong growth potential make it an attractive option for investors looking to capitalize on the burgeoning medical tech industry, including stocks and shares.
